In this article, we will look at the 11 Most Profitable NYSE Stocks to Buy Right Now.On December 12, Adam Parker, Trivariate Research founder and CEO, appeared on CNBC’s ‘Squawk on the Street’ to talk about his view on the ‘buy high and sell low’ mantra. He was of the view that valuation doesn’t work for picking stocks, as we have seen that we cannot buy super cheap stocks.Similarly, one can also not buy stocks that are down from 52 week highs because of underperformance. According to him, buy low, sell hig ...

Core Insights - Novartis AG announced results from the VAYHIT2 Phase 3 trial of ianalumab plus eltrombopag for patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids [1][5] Group 1: Trial Results - Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45%, with a median time to treatment failure of 13.0 months compared to 4.7 months for placebo plus eltrombopag [2] - The sustained platelet count improvement rate at six months was significantly higher for ianalumab plus eltrombopag at 62% versus 39% for placebo plus eltrombopag [4] - Fatigue improvement was also noted, with a mean reduction of 7.7 points for ianalumab plus eltrombopag compared to 3.6 points for placebo plus eltrombopag [4] Group 2: Additional Insights - The estimated probability of being free from treatment failure at 12 months was 54% in the 9-mg group, 51% in the 3-mg group, and 30% in the placebo group [5] - Ianalumab is under investigation for other B-cell-driven autoimmune diseases, with ongoing Phase 3 trials in first-line ITP and in second and later lines of warm autoimmune hemolytic anemia, with results expected in 2026 [5] - Novartis stock increased by 1.46% to $132.07 at the time of publication [5]

Core Insights - Novartis announced positive results from the VAYHIT2 Phase III trial, showing that ianalumab plus eltrombopag significantly improved disease control in patients with primary immune thrombocytopenia (ITP) compared to placebo [1][6][8] Group 1: Trial Results - Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45%, with a median time to treatment failure of 13.0 months compared to 4.7 months for placebo plus eltrombopag [1][6] - 62% of patients receiving ianalumab plus eltrombopag achieved sustained platelet count improvement at six months, compared to 39% for placebo plus eltrombopag [3][5] - The trial demonstrated a mean reduction in fatigue of 7.7 points with ianalumab plus eltrombopag versus 3.6 points with placebo plus eltrombopag [3] Group 2: Mechanism and Administration - Ianalumab targets B cells through a dual mechanism, depleting B cells while blocking survival signals, which is crucial for managing ITP [4][9] - The treatment regimen consists of four once-monthly intravenous doses, potentially reducing the need for chronic therapy [6][8] Group 3: Safety and Tolerability - Ianalumab was well tolerated, with adverse events comparable to placebo, the most common being headache and infusion-related reactions [7] - Neutropenia occurred more frequently in the ianalumab groups but most cases resolved without treatment [7] Group 4: Future Plans - Novartis plans to submit VAYHIT2 data along with results from the ongoing first-line ITP trial, VAYHIT1, to health authorities in 2027 [6][8]